Panel Discussion: Overcoming Design Challenges in Next-Generation Oligonucleotides to Maximize Selectivity, Potency & Clinical Impact

• What design strategies are most effective in mitigating off-target effects?
• How do teams prioritize stability vs. delivery vs. potency?
• What are the emerging trends in oligonucleotide chemistry for next-generation therapeutics?

Speakers:

Ganesh Iyer

Chief Executive Officer & Founder

Opprtna Therapeutics

Utsav Saxena

Head of Systems Biology

Novo Nordisk